



ELSEVIER
SAUNDERS

Dermatol Clin 22 (2004) 509–525

DERMATOLOGIC
CLINICS

Cumulative Index 2004

Volume 22

January	GERIATRIC DERMATOLOGY, pages 1–130
April	THE CLINICAL USE OF BOTULINUM TOXIN, pages 131–230
July	BIOTERRORISM, pages 231–338
October	PSORIASIS, pages 339–525

Note: Page numbers of article titles are in **boldface** type.

A

- ACAM1000 vaccine, for smallpox, 286
- Acantholytic dermatosis, in elderly, 77, 119–120
- Acanthosis nigricans, in elderly, 24
- Accutane, for psoriasis, 403. *See also* Retinoids.
- Acitretin, for psoriasis, 383–384. *See also* Retinoids.
with ultraviolet B therapy, 468
- Acrodermatitis enteropathica, in elderly, 29
- Acticin, for scabies, in elderly, 8
- Actinic elastosis, in elderly, 115–116
- Acyclovir, for herpes zoster, in elderly, 52
for postherpetic neuralgia, in elderly, 54
- Addison's disease, in elderly, 26
- S-Adenosylhomocysteine hydrolase inhibitors, for hemorrhagic fever viruses, 298
- Adrenal dysfunction, in elderly, 26
- Aethoxysclerol, in sclerotherapy, for varicosities, 502
- Alefacet, for psoriasis, **407–426**
chronic plaque psoriasis, 408–422
adverse effects of, 419–421
and infections, 420
and malignancies, 420
duration of response in, 411–412
efficacy of, 408–409
immune responses to, 421–422
immunogenicity of, 421
- memory T-cell reductions and,
412–413, 415
- multiple courses of, 418–419
- pharmacodynamics of, 412, 415
- prior treatment history and response in,
410–411
- quality-of-life issues in, 415–417
- refractory disease, 411, 418
- safety and tolerability of, 417
- severe disease, 409–410
- T-cell variability in, 415
- with immunosuppressants, 417–418
- with ultraviolet B, 422
- mechanism of action of, 407–408
- psoriatic arthritis, 422–423, 481
- rheumatoid arthritis, 423
- Allergic reactions, to complementary and alternative medicine, 327
- Aminoglycosides, indications for, in elderly, 68
- Anal fissures, Botox injections for, 192
- Analgesics, for postherpetic neuralgia, in elderly, 53
- Anesthesia, in Botox injections, for hyperhidrosis,
179–180
- Angular cheilitis, in elderly, 37
- Anthralin, for psoriasis, 380
- Anthrax, in bioterrorism, 243–244, **247–255**
cutaneous, 249–250, 251, 252
diagnosis of, 250–251
differential diagnosis of, 251–252
epidemiology of, 248

- gastrointestinal, 250, 251, 252
historical aspects of, 247–248
inhalational, 250, 251, 252
intestinal, 250
management of, 252
opharyngeal, 250
pathogenicity of, 248–249
prevention of, 252–253
vaccine for, 253–254
- Anthrax Vaccine Absorbed, for anthrax, 253
- Anticlotting therapy, and cutaneous surgery, in elderly, 99
- Antidepressants, for postherpetic neuralgia, in elderly, 54
- Antifungal agents, indications for, in elderly, 68
- Antigen-presenting cells, in immunopathogenesis, of psoriasis, 352, 372
- Anti-inflammatory agents, for pemphigus vulgaris, in elderly, 74–75
- Antimicrobial therapy, for plague, 309–310
for tularemia, 317–318
in elderly, 63–71
antifungal agents in, 68
antiviral agents in, 68
drug interactions in, 66
fluoroquinolones in, 68
for cutaneous infections, 57–58
 β -lactams in, 67
metronidazole in, 68
pharmacokinetics of, 63, 65–66
resistance to, 68–70
consequences of, 69–70
control of, 70–71
mechanisms of, 69
risk factors for, 69
- RNA synthesis antibiotics in, 67–68
social issues in, 66–67
- Antiplatelet therapy, and cutaneous surgery, in elderly, 99
- Antiviral agents, for herpes zoster, in elderly, 52
for postherpetic neuralgia, in elderly, 54
indications for, in elderly, 68
- Arenaviridae, in bioterrorism. *See* Hemorrhagic fever viruses.
- Arnica montana*, in complementary and alternative medicine, 330
- Arterial insufficiency, of leg, in elderly, 19
- Arthralgias, retinoids and, 470
- Arthritis, psoriatic. *See* Psoriatic arthritis.
- rheumatoid, alefacept for, 423
infliximab for, 442
- Asteatotic eczema, in elderly, 2, 17, 116–117
- Astragalus root, in complementary and alternative medicine, 329
- Athlete's foot, in elderly, 15, 41–44
- Atopic dermatitis, as contraindication, to smallpox vaccination, 284
in elderly, 2
- Atrophic candidiasis, in elderly, 36–37
- Aum Shinrikyo, in bioterrorism, 241
- Autoimmune diseases, as contraindication, to smallpox vaccination, 285
- Autoimmunity, etanercept and, 454
- Azole agents, for onychomycosis, in elderly, 48, 57
for tinea versicolor, in elderly, 38
indications for, in elderly, 68
-
- B**
- Bacille Calmette-Guérin, in complementary and alternative medicine, 330
- Back pain, Botox injections for, 191
- Balanitis, candidal, in elderly, 41
- Basal cell carcinoma, in elderly, 16
- Benign cramp-fasciculation syndrome, Botox injections for, 187–188
- Benign familial pemphigus, in elderly, 77
- Beta-lactams, for plague, 310
- Biologic therapy, for psoriasis, 371–377. *See also* specific agents, e.g., Etanercept.
monoclonal antibodies in, 374–375
targets for, 375–376
blocking T-cell activation, 375
immune deviation away from T cells, 375
inactivating cytokines and chemokines, 375–376
pathogenic T cells, 375
with phototherapy, 404
for psoriatic arthritis, 480–481
- Biological Weapons Convention, on bioterrorism, 238
- Biopsy, of skin cancer, in elderly, 96
- Bioterrorism, anthrax in. *See* Anthrax.
hemorrhagic fever viruses in. *See* Hemorrhagic fever viruses.

- historical aspects of, 231–246
biocides, 240–244
anthrax attacks of 2001, 243–244
Aum Shinrikyo, 241
Dark Harvest, 241
Larry Wayne Harris, 242
Minnesota Patriots Council, 241–242
Rajneeshes, 241
R.I.S.E., 242
early history, 232–233
contamination, 232
infected fabrics, 233
projectile biologic weapons, 232–233
post–World War I through World War II,
234–237
Britain, 236
Canada, 236
France, 236
Germany, 236
Japan, 235–236
Russia, 236–237
United States, 234–235
post–World War II and beyond, 237–240
1972 Biological Weapons Convention,
237–238
Iraq, 239–240
Soviet Union/Russia, 238–239
United States, 237–238
World War I, 233–234
1925 Geneva Protocol, 234
plague in. *See* Plague.
response to, dermatologist's role in, 321–324
ricin in. *See* Ricin.
smallpox in. *See* Smallpox.
staphylococcal enterotoxin B in. *See*
Staphylococcal enterotoxin B.
trichothecene mycotoxins in. *See*
Trichothecene mycotoxins.
tularemia in. *See* Tularemia.
- Bleeding disorders, hemorrhagic fever viruses and,
295–296
- Blepharospasm, Botox injections for, 191
- Blistering diseases, in elderly, 73–86
bullous pemphigoid, 77–78
cicatricial pemphigoid, 78–79
coma bullae, 82
dermatitis herpetiformis, 81–82
diabetic bullae, 83
drug-related, 82
epidermolysis bullosa acquisita, 79–80
linear IgA bullous disease, 81
- pemphigus, 73–77
Hailey-Hailey disease, 77
paraneoplastic pemphigus, 75–76
pemphigus foliaceus, 75
pemphigus vulgaris, 74–75, 120–121
subcorneal pustular dermatosis and IgA
pemphigus, 76
transient acantholytic dermatosis, 77,
119–120
porphyria cutanea tarda, 80–81
stasis blisters, 82–83
- BoNT-A injections, for headaches. *See* Headaches.
- Botox injections, complications of, 197–205. *See*
also specific indications.
in cosmetic procedures, 199–203
muscle spasms, 198
resistance to toxin, 198–199
dilution and storage of, 135–136
electromyographic guidance for, 136
for glabellar rhytides. *See* Glabellar rhytides.
for hyperhidrosis. *See* Hyperhidrosis.
in eyes and eyebrows. *See* Eyes and eyebrows.
in face and neck. *See* Face and neck.
indications for, in elderly, 105–106
informed consent for, 203
noncosmetic indications for, 187–195
gastrointestinal disorders, 192
genitourinary disorders, 191–192
laryngeal disorders, 189–190
neurologic disorders, 187–189
ophthalmologic disorders, 191
oromandibular disorders, 192
pain syndromes, 190–191
salivary disorders, 191
- Botulinum neurotoxin injections, for headaches.
See Headaches.
- Botulinum toxin A injections. *See* Botox injections;
Dysport injections.
- Botulinum toxin B injections. *See* Myobloc injections.
- Botulinum toxin therapy, historical aspects of,
131–133
Carruthers, 132
Drachman, 132
for cosmetic indications, 132
for Frey's syndrome, 132
for hyperhidrosis, 132
for strabismus, 132
for torticollis, 132
from warfare to therapy, 131–132
Kerner, 131
Myobloc, 133
van Ermengem, 131

Breast-feeding, and hemorrhagic fever viruses, 294
Brow ptosis, Botox injections and, 143, 147, 148, 200
Bruxism, Botox injections for, 192
Bubonic plague, in bioterrorism, 305
Bullous diabetorum, in elderly, 83
Bullous disease of comatose, in elderly, 82
Bullous pemphigoid, in elderly, 77–78
Bunions, in elderly, 14
Bunny lines, Botox injections for, 153
Bunyaviridae, in bioterrorism. *See* Hemorrhagic fever viruses.
Burdock, in complementary and alternative medicine, 327

C

Calcipotriene, for psoriasis, 380
with phototherapy, 380, 402
with psoralen plus ultraviolet A therapy, 380
Calluses, of foot, in elderly, 13–14
Candidal balanitis, in elderly, 41
Candidal diseases, complementary and alternative medicine for, 328
Candidal intertrigo, in elderly, 40–41
Candidal paronychia, in elderly, 44–45
Candidal vulvovaginitis, in elderly, 41
Candidiasis, oral, in elderly, 36–37
Carbapenems, indications for, in elderly, 67
Carbocyclic 3-deazaadenosine, for hemorrhagic fever viruses, 298
Carbon dioxide lasers, in skin resurfacing, in elderly, 104
Cardiac disease, and cutaneous surgery, in elderly, 98–99
Cardiomyopathy, nonischemic dilated, smallpox vaccination and, 283–284
Cardiovascular disease, as contraindication, to smallpox vaccination, 285
Castor bean, in bioterrorism. *See* Ricin.
CD1d expression, in immunopathogenesis, of psoriasis, 356
Central nervous system complications, of smallpox vaccination, 282

Cephalosporins, indications for, in elderly, 67
Cerebral palsy, spasticity in, Botox injections for, 189
Cervical dystonia, Botox injections for, 187
Cheilitis, angular, in elderly, 37
Chemical peels, in elderly, 105
Chemokines, and biologic therapy, for psoriasis, 375–376
in immunopathogenesis, of psoriasis, 373
Cherry angiomas, in elderly, 106
Chickweed, in complementary and alternative medicine, 329
Chloramphenicol, for plague, 310
for tularemia, 317–318
Chromated glycerin, in sclerotherapy, for varicosities, 502
Chromosome 6p21, in psoriasis. *See* Psoriasis, genetics of.
Cicatricial pemphigoid, in elderly, 78–79
Cidofovir, for smallpox, 272, 280–281
Ciprofloxacin, for cutaneous anthrax, 252
Claw toes, in elderly, 14
Clindamycin, indications for, in elderly, 68
Coma bullae, in elderly, 82
Complementary and alternative medicine, 325–332
allergic reactions in, 327
antiinflammatory herbs in, 327–328
approach to, 326–327
Arnica montana in, 330
astragalus root in, 329
bacille Calmette-Guérin in, 330
burdock in, 327
chickweed in, 329
for candidal and inflammatory diseases, 328
for food allergies, 328
for itching disorders, 329
for melanoma, 330
Gerson Program in, 330
homeopathy in, 329–330
licorice in, 327–328
MGN3 in, 329
nettles in, 329
plantain in, 329
rationale for, 325–326
reishi mushrooms in, 329
Rhus tox in, 330
silymarin in, 327

- to stimulate immune response, 329
with pharmacologic therapy, 329
- Compression**, in sclerotherapy, for varicosities, 504
- Congestive heart failure**, etanercept and, 454
infliximab and, 443
- Contact dermatitis**, in elderly, 18
- Contact vaccinia**, smallpox vaccination and, 282–283
- Corns**, in elderly, 13–14
- Corrugator supercilii muscle**, Botox injections in, 138
- Cosmetic surgery**, in elderly. *See Cutaneous surgery.*
- Cricopharyngeal dysfunction**, Botox injections for, 190
- Crohn's disease**, infliximab for, 442
- Crow's feet**, Botox injections for, 148–149
complications of, 201–202
Dysport injections for, 216
- Cushing's syndrome**, in elderly, 26
- Cutaneous anthrax**, in bioterrorism, 249–250, 251, 252
- Cutaneous infections**, in elderly, 51–61
antimicrobial therapy for. *See*
Antimicrobial therapy.
herpes zoster, 51–53
of lower extremities. *See Lower extremities.*
onychomycosis, 16, 45–49, 51, 56–57
postherpetic neuralgia, 51, 53–54, 56
- Cutaneous surgery**, in elderly, 97–113
cosmetic surgery, 103–107
for focal skin lesions, 106
for rhytides and sagging, 105–106
for skin resurfacing, 104–105
psychologic issues in, 106–107
long-term follow-up of, 109
medically necessary dermatologic surgery, 103
morbid conditions and, 103
perioperative care for, 107–108
polypharmacy and, 101–102
postoperative care for, 108–109
pre-existing disease and, 98–101
cardiac disease, 98–99
diabetes mellitus, 100
functional status, 99–100
hepatic disease, 100–101
hypertension, 100
musculoskeletal disease, 99
neurologic disease, 101
- pulmonary disease, 99
renal disease, 99
thyroid disease, 100
previous surgery and, 102
prosthetics and, 102
- Cutaneous T-cell lymphoma**, in elderly, 3
- Cyclosporine**, for psoriasis, 384
with etanercept, 455
with psoralen plus ultraviolet A therapy, 404
for psoriatic arthritis, 479
- Cytokines**, and biologic therapy, for psoriasis, 375–376
in immunopathogenesis, of psoriasis, 354
- D**
- Dapsone**, for linear IgA bullous disease, in elderly, 81
- Darier's disease**, in elderly, 2
- Dark Harvest**, in bioterrorism, 241
- Decubitus ulcers**, in elderly, 87–91
diagnosis of, 88
evaluation of, 89
location of, 88
morphology of, 87–88
nomenclature of, 87
prevention of, 89–90
- Delusions of parasitosis**, in elderly, 19
- Demyelination disorders**, etanercept and, 454
infliximab and, 443
- Dendritic cells**, in immunopathogenesis, of psoriasis, 353–354
- Depressor anguli oris muscle**, Botox injections in, 153
- Depressor supercilii muscle**, Botox injections in, 139
- Dermabrasion**, in elderly, 104–105
- Dermatitis**, as contraindication, to smallpox vaccination, 284
in elderly, 2, 3, 18–19, 33
- Dermatitis herpetiformis**, in elderly, 81–82
- Dermatologic lesions**, in elderly, 115–123
asteatotic eczema, 2, 17, 116–117
lichen sclerosis et atrophicus, 117–118
pemphigus vulgaris, 74–75, 120–121
solar elastosis, 115–116
transient acantholytic dermatosis, 77, 119–120
- Dermatology Life Quality Index**, in psoriasis, 390

- Dermatology Quality-of-Life Scales, in psoriasis, 390
- Dermopathy, diabetic, in elderly, 23
- Detergents, in sclerotherapy, for varicosities, 501
- Diabetes mellitus, and cutaneous surgery, in elderly, 100
- cutaneous manifestations of, in elderly, 23–25
 acanthosis nigricans, 24
 diabetic dermopathy, 23
 eruptive xanthomas, 24
 necrobiosis lipoidica diabetorum, 24
 perforating dermatosis, 24
 scleredema diabetorum, 24–25
 ulcers, 23–24
- Diabetic bullae, in elderly, 83
- Diabetic foot, in elderly, 15
- Digital deformities, in elderly, 14
- Dilated cardiomyopathy, nonischemic, smallpox vaccination and, 283–284
- Doxycycline, for plague, 310
 for tularemia, 317–318
- Drinking water contamination, in bioterrorism, 232
- Drug reactions, in elderly, 3
- Dryvax, for smallpox, 277
- Duane retraction syndrome, Botox injections for, 191
- Duffy classification, of varicosities, 500
- Dysphonia, mutational, Botox injections for, 189
 spasmodic, Botox injections for, 189
- Dysport injections, 213–219
 biologic activity of, 214
 cosmetic indications for, 216
 in face and neck, 151–152
 masseteric hypertrophy, 155
 dilution and storage of, 135–136, 214
 electromyographic guidance for, 136
 immunogenicity of, 214
 manufacturing of, 213–214
 noncosmetic indications for, 214–216
 hyperhidrosis, 215–216
 lichen simplex, 216
 salivary disorders, 216
 striated and smooth muscle disorders, 215
 thyroid eye disease, 216
- Dystonia, Botox injections for, 187
 complications of, 198
- oromandibular, Botox injections for, 192

E

- Ebola virus, in bioterrorism. *See* Hemorrhagic fever viruses.
- Ecchymosis, Botox injections and, 147, 149
- Eccrine skin cancer, in elderly, 95
- Eczema vaccinatum, smallpox vaccination and, 281
- Eczematous diseases, as contraindication, to smallpox vaccination, 284
- in elderly, 1–5
 asteatotic eczema, 2, 17, 116–117
 atopic dermatitis, 2
 cutaneous T-cell lymphoma, 3
 Darier's disease, 2
 drug reactions, 3
 eczema herpeticum, 2
 intertrigo, 3, 40–41
 nummular eczema, 2
 psoriasis, 3
 scabies. *See* Scabies.
 seborrheic dermatitis, 3, 33
 stasis dermatitis, 3, 18–19
- Edema, sclerotherapy and, 504
- Efalizumab, for psoriasis, 427–435
 dosing of, 433–434
 immunobiologic activity of, 427–428
 intermediate-term results of, 430–431
 long-term results of, 431–432
 mechanism of action of, 427–428
 phase 3 clinical experience with, 428
 safety of, 432–433
 short-term results of, 428, 430
- Elimite, for scabies, in elderly, 8
- Encephalitis, smallpox vaccination and, 282
- Encephalomyelitis, smallpox vaccination and, 282
- Endocrine-metabolic disorders, cutaneous manifestations of, in elderly, adrenal dysfunction, 26
 diabetes mellitus. *See* Diabetes mellitus.
 parathyroid disease, 27–28
 pituitary disorders, 26–27
 thyroid disorders, 25–26
- Enterotoxins, staphylococcal, in bioterrorism. *See* Staphylococcal enterotoxins.
- Environmental factors, in psoriatic arthritis, 478
- Enzyme-linked immunosorbent assay, of hemorrhagic fever viruses, 297
- Epidermal skin cancer, in elderly, 94

- Epidermolysis bullosa acquisita, in elderly, 79–80
- Erbium:YAG lasers, in skin resurfacing, in elderly, 104
- Erosio interdigitalis blastomycetica, in elderly, 41
- Eruptive exanthomas, in elderly, 24
- Erythema, in elderly, 106
- Escharotic compounds, for skin cancer, in elderly, 95
- Estrogen supplementation, topical, for skin disorders, in menopause, 29–30
- Etanercept**, for psoriasis and psoriatic arthritis, 449–455, 480–481
 and autoimmunity, 454
 and congestive heart failure, 454
 and demyelination disorders, 454
 and infections, 453
 and malignancies, 453
 dosing of, 451
 efficacy of, 451–452
 immunization during, 454
 in combination therapy, 455, 457
 in pregnancy and lactation, 454
 indications for, 450–451
 injection site reactions to, 452–453
 laboratory tests for, 453
 mechanism of action of, 449–450
 monotherapy dosing of, 454–455
 radiographic response to, 451–452
 safety of, 452–454
 self-administration of, 454
 structure and function of, 450
 tuberculin testing for, 453–454
 with cyclosporine, 455
 with retinoids, 469
- Ethamolin, in sclerotherapy, for varicosities, 502
- Ethanolamine oleate, in sclerotherapy, for varicosities, 502
- Etretinate, for psoriasis, 383–384.
See also Retinoids.
 for psoriatic arthritis, 479
- Excoriations, neurotic, in elderly, 19
- Exfoliative erythrodermic psoriasis, retinoids for, 467
- Exfoliative skin conditions, as contraindication, to smallpox vaccination, 284
- Eyebrows. *See* Eyes and eyebrows.
- Eyelid ptosis, Botox injections and, 143, 200

- Eyes and eyebrows, Botox injections in, 145–149
 anatomic boundaries in, 145
 complications of, 147–148
 brow ptosis, 143, 147, 148, 200
 cockeyed appearance, 147–148, 201
 ecchymosis, 147, 149
 dosage for, 148
 for deep zygomaticus lines, 149
 for periorbital rhytides, 148–149
 high versus low concentration in, 147
 location of, 145–146

F

- Fabrics, infected, in bioterrorism, 243
- Face and neck, Botox injections in, 151–158
 complications of, 156, 202–203
 contraindications to, 152
 dosage for, 152
 for bunny lines and nasal flare, 153
 for facial asymmetry, 155
 for horizontal neck lines, 156
 for hypertrophic orbicularis oculi, 152
 for masseteric hypertrophy, 155
 for mental crease and peau d'orange chin, 154–155
 for mouth frown and melolental fold, 153–154
 for nasolabial folds, 153, 202
 for neck lines and bands, 159–166
 aging neck in, 159–161
 anatomy in, 161–162
 complications of, 164–165
 results of, 164
 technique for, 162–163
 for perioral rhytides, 153
 for platysmal lines, 155–156, 161–162
 for smile lines, 155
 for upper gum show, 155
 for vertical platysmal bands, 156
 formulations for, 151–152
 indications for, 152
 side effects of, 156
- Dysport injections in, 151–152
- Myobloc injections in, 151, 163, 165
- Facial asymmetry, Botox injections for, 155
- Facial myokymia, Botox injections for, 189
- Facial nerve paralysis, synkinesis after, Botox injections for, 189
- Famciclovir, for herpes zoster, in elderly, 52–53
 for postherpetic neuralgia, in elderly, 54
- Filoviridae, in bioterrorism. *See* Hemorrhagic fever viruses.

- Fissures, anal, Botox injections for, 192
FK506, for psoriasis, 384
Flagyl, indications for, in elderly, 68
Flaviviridae, in bioterrorism. *See* Hemorrhagic fever viruses.
Fluoroquinolones, for plague, 309
for tularemia, 318
indications for, in elderly, 68
Food allergies, complementary and alternative medicine for, 328
Foot dermatoses, in elderly, 13–15
Francisella tularensis, in tularemia, 313–314
Frey's syndrome, Botox injections for, historical aspects of, 132
Frontalis muscle, Botox injections in, 137–138
complications of, 200
Fungal infections, in elderly, 33–50
candidal intertrigo, 40–41
candidal paronychia, 44–45
candidal vulvovaginitis and balanitis, 41
onychomycosis, 16, 45–49, 51, 56–57
oral candidiasis, 36–37
seborrheic dermatitis, 3, 33
tinea capitis, 33–36
tinea corporis, 39–40
tinea cruris, 40
tinea pedis, 15, 41–44
tinea versicolor, 37–39
- G**
- Gastrointestinal anthrax, in bioterrorism, 250, 251, 252
Gastrointestinal disorders, Botox injections for, 192
Gastrointestinal tularemia, in bioterrorism, 315
Generalized vaccinia, smallpox vaccination and, 280–281
Geneva Protocol, for bioterrorism, 234
Genitourinary disorders, Botox injections for, 191–192
Genomic data, on psoriasis, 361–363
Gentamicin, for plague, 310
for tularemia, 317, 318
Gerson Program, in complementary and alternative medicine, 330

- Glabellar rhytides, Botox injections for, 137–144
anatomy in, 137–139
corrugator supercilii muscle, 138
frontalis muscle, 137–138, 200
glabellar complex, 138
orbicularis oculi muscle, 139, 148, 152
procerus and depressor supercilii muscles, 139
complications of, 141, 143, 200
brow ptosis, 143, 200
eyelid ptosis, 143, 200
initial clinical trials of, 137
injection sites and dosages in, 139–140
injection techniques for, 140–141
patient assessment and education for, 139
results of, 141
Dysport injections for, 216
Glandular tularemia, in bioterrorism, 315, 317
Glottic stertosis, Botox injections for, 190
Glycerin, chromated, in sclerotherapy, for varicosities, 502
Gold, parenteral, for psoriatic arthritis, 480
Granulomas, laryngeal, Botox injections for, 189
postzoster, in elderly, 56
Graves' disease, in elderly, 25
Gravimetric measurements, of hyperhidrosis, 177, 178
Griseofulvin, for tinea capitis, in elderly, 36

H

- Hailey-Hailey disease, in elderly, 77
Hallux limitus, in elderly, 14
Hammer toes, in elderly, 14
Harris, Larry Wayne, in bioterrorism, 242
Headaches, BoNT-A injections for, 167–175
dosage and administration of, 173
efficacy of, placebo-controlled trials of, 172–173
retrospective reviews and open-label trials of, 169, 172
mechanism of action of, 168–169
patient selection for, 167
tolerability of, 173
Botox injections for, 191
complications of, 203
Heart disease, and cutaneous surgery, in elderly, 98–99
Heat shock proteins, in immunopathogenesis, of psoriasis, 355

- Helomata, in elderly, 13–14
- Hemorrhagic fever viruses, in bioterrorism, 291–302
breast-feeding and, 294
clinical features of, 295–296
diagnosis of, 297–298
ecology of, 295
epidemiology of, 294–295
historical aspects of, 292–293
infection control measures for, 298
management of, 298
pathogenicity of, 296–297
postexposure prophylaxis for, 298–299
prevention of, 298–299
reservoirs for, 295
transmission of, 294–295
vaccine for, 299
virology of, 293–294
- Hepatic disease, and cutaneous surgery, in elderly, 100–101
- Hepatotoxicity, of methotrexate, 383
of retinoids, 471
- Herbal therapy, in dermatology. *See* Complementary and alternative medicine.
- Herpes zoster, in elderly, 51–53
- HIV infection, in elderly, 30
- HLA antigens, in psoriatic arthritis, 477–478
- Homeopathy, in complementary and alternative medicine, 329
- Hydroxyurea, for psoriasis, 385
- Hyperhidrosis, Botox injections for, 177–185, 191
anesthesia in, 179–180
complications of, 203
documentation of problem in, 177–179
gravimetric measurements in, 177, 178
Minor starch-iodine test in, 178–179
duration of effect in, 182
future directions in, 183
historical aspects of, 132
pattern and dosage for, 181–182
scheduling of, 182–183
syringes for, 180
technique for, 180–181
- Dysport injections for, 215–216
- Hyperkeratosis, in elderly, 13
- Hyperlacrimation, Botox injections for, 191
- Hyperlipidemia, retinoids and, 471
- Hyperparathyroidism, in elderly, 27
- Hyperpigmentation, sclerotherapy and, 504
- Hyperpituitarism, in elderly, 27
- Hypertension, and cutaneous surgery, in elderly, 100
- Hyperthyroidism, in elderly, 25
- Hypertonic saline, in sclerotherapy, for varicosities, 501
- Hypoparathyroidism, in elderly, 27–28
- Hypopituitarism, in elderly, 26–27
- Hypothyroidism, in elderly, 25–26
and cutaneous surgery, 100
-
- I**
- IgA pemphigus, in elderly, 76
- Immune cascade, in immunopathogenesis, of psoriasis, 373–374
- Immune deficiency, as contraindication, to smallpox vaccination, 281–282, 284–285
- Immune response, stimulation of, complementary and alternative medicine in, 329
- Immunization, etanercept and, 454
- Immunohistochemical staining, of hemorrhagic fever viruses, 297–298
- Immunomodulatory agents, for psoriasis, with retinoids, 468–469
- Immunosuppressive therapy, for bullous pemphigoid, in elderly, 78
for cicatricial pemphigoid, in elderly, 79
for pemphigus vulgaris, in elderly, 74–75
for psoriasis, with alefacept, 417–418
- Infections, alefacept and, 420
cutaneous, in elderly. *See* Cutaneous infections.
etanercept and, 453
fungal, in elderly. *See* Fungal infections.
prevention of, in elderly. *See* Antimicrobial therapy.
- Inflammatory disease, complementary and alternative medicine for, 328
- Infliximab, for Crohn's disease, 442
for psoriasis, 437–447
and congestive heart failure, 443
and demyelinating diseases, 443
and formation of anti-infliximab antibodies, 443–444
and reactivation of latent tuberculosis, 443

case series of, 441–442
mechanism of action of, 439
randomized controlled clinical trials of,
439–440
safety and tolerability of, 442–443
sustained efficacy of, 440
uncontrolled open-label clinical trials of,
440–441
for psoriatic arthritis, 480
for rheumatoid arthritis, 442

Inhalational anthrax, in bioterrorism, 250, 251, 252

Insulin, for diabetes, adverse effects of, in elderly, 25

Interdigital candidiasis, in elderly, 41

Interdigital tinea pedis, in elderly, 42

Interferon-gamma, in immunopathogenesis of
psoriasis, 351–353, 356, 358

Intertrigo, in elderly, 3, 40–41

Intestinal anthrax, in bioterrorism, 250

Iodine, polyiodinated, in sclerotherapy, for
varicosities, 502

Isotretinoin, for psoriasis, 383–384.
See also Retinoids.

Itching disorders, complementary and alternative
medicine for, 329

Itraconazole, for onychomycosis, in elderly, 48, 57

Ivermectin, for scabies, in elderly, 9

K

Kaposi's varicelliform eruption, in elderly, 2
Kidney disease, and cutaneous surgery, in elderly, 99

L

β-Lactams, indications for, in elderly, 67

Lactation, etanercept in, 454

Laryngeal disorders, Botox injections for, 189–190

Laser therapy, for skin cancer, in elderly, 95

Lasers, in skin resurfacing, in elderly, 104
postoperative care for, 108–109

LC16m8 vaccine, for smallpox, 287

Leflunomide, for psoriatic arthritis, 479

Leg dermatoses, in elderly, 17–19

Lentigines, in elderly, 106

Lice, in elderly. *See* Pediculosis.

Lichen planus, of foot, in elderly, 14

Lichen sclerosis et atrophicus, in elderly, 117–118

Lichen simplex, Dysport injections for, 216

Lichen simplex chronicus, in elderly, 19

Licorice, in complementary and alternative medicine,
327–328

Lidocaine, for postherpetic neuralgia, in elderly, 53

Lindane, for scabies, in elderly, 8

Linear IgA bullous disease, in elderly, 81

Linezolid, for cutaneous infections, in elderly, 57–58

Liver disease, and cutaneous surgery, in elderly,
100–101

Low back pain, Botox injections for, 191

Lower extremities, cutaneous diseases of, in elderly,
13–21

- foot dermatoses, 13–15
- infections, 15
- leg dermatoses, 17–19
- malignancies, 16–17
- nail changes, 15–16, 45–49, 51, 56–57
- psychologic disorders, 19

Lymphoma, cutaneous T-cell, in elderly, 3

M

Macrolide antibiotics, indications for, in elderly,
67–68

Magnetic resonance imaging of, of psoriatic
arthritis, 476

Malignancies, alefacept and, 420
cutaneous, in elderly, 16–17
etanercept and, 453

Mallet toes, in elderly, 14

Marburg hemorrhagic fever, in bioterrorism. *See*
Hemorrhagic fever viruses.

Masseteric hypertrophy, Botox injections for, 155

Melanocytic skin cancer, in elderly, 94, 96

Melanoma, complementary and alternative medicine
for, 330

Melolabial folds, Botox injections for, 153

Melomental folds, Botox injections for, 154

Meningitis, plague, in bioterrorism, 306

Menopause, cutaneous manifestations of, 29–30
 Mental crease, Botox injections for, 154–155
 Methotrexate, for psoriasis, 382–383, 403–404
 with psoralen plus ultraviolet A therapy, 404
 for psoriatic arthritis, 479, 480
 Metronidazole, indications for, in elderly, 68
 MGN3, in complementary and alternative medicine, 329
 Migraine headaches. *See* Headaches.
 Minnesota Patriots Council, in bioterrorism, 241–242
 Minor starch-iodine test, for hyperhidrosis, 178–179
 Moccasin-type tinea pedis, in elderly, 42–43
 Mohs' micrographic surgery, for skin cancer, in elderly, 95–96
 Mouth frown, Botox injections for, 153
 Mucocutaneous toxicity, of retinoids, 470
 Mucous membrane pemphigoid, in elderly, 78–79
 Muscle spasms, Botox injections and, 198
 Musculoskeletal disease, and cutaneous surgery, in elderly, 99
 Musculoskeletal headaches, Botox injections for, 191
 Mutational dysphonia, Botox injections for, 189
 Myalgias, retinoids and, 470
 Mycophenolate mofetil, for psoriasis, 385
Myobloc injections, 207–211
 clinical studies of, 209
 cost of, 210
 equivalency studies of, 209
 formulation for, 207–208
 in face and neck, 151, 163, 165
 indications for, 209–210
 rapid action of, 210
 side effects of, 210
 stability of, 210
 versus Botox injections, 208–210
 duration of effect, 208–209
 increased pain, 209–210
 increased radius of diffusion, 208
 rate of onset, 208
 Myocardial infarction, smallpox vaccination and, 283
 Myocarditis, smallpox vaccination and, 283
 Myoclonus, palatal, Botox injections for, 189
 Myokymia, Botox injections for, 189

N

Nail disorders, in elderly, 15–16, 45–49, 51, 56–57
 Nasal flare, Botox injections for, 153
 Nasolabial folds, Botox injections for, 153
 complications of, 202
 Natural killer cells, in immunopathogenesis, of psoriasis, 354, 356
 Neck. *See* Face and neck.
 Necrobiosis lipoidica diabetorum, in elderly, 24
 Nephrotoxicity, of cyclosporine, 384
 Nettles, in complementary and alternative medicine, 329
 Neurodermatitis, in elderly, 19
 Neurologic disorders, and cutaneous surgery, in elderly, 101
 Botox injections for, 187–189
 Neuropathy, diabetic, in elderly, 24
 Neurotic excoriations, in elderly, 19
 Neutralizing antibodies, formation of, Botox injections and, 152, 198–199
 Niacin deficiency, in elderly, 28–29
 Nix, for scabies, in elderly, 8
 Non-major histocompatibility complex susceptibility loci, in psoriasis, 343–344
 Nonablative skin resurfacing, in elderly, 104
 Nummular eczema, in elderly, 2
 Nutritional deficiencies, cutaneous manifestations of, in elderly, 29–30
 Nystagmus, Botox injections for, 191

O

Ocular vaccinia, smallpox vaccination and, 280
 Oculoglandular tularemia, in bioterrorism, 315
 Onychomycosis, in elderly, 16, 45–49, 51, 56–57
 Ophthalmologic disorders, Botox injections for, 191
 Ophthalmologic toxicity, of retinoids, 471
 Orbicularis oculi muscle, Botox injections in, 139, 148, 152
 Orbicularis oris myokymia, Botox injections for, 189
 Oromandibular disorders, Botox injections for, 192
 Oropharyngeal anthrax, in bioterrorism, 250

- Oropharyngeal tularemia, in bioterrorism, 315, 317
- Osmotic agents, in sclerotherapy, for varicosities, 501
- Oxazolidinone antibiotics, for cutaneous infections, in elderly, 57–58
- P**
- Pacemakers, and cutaneous surgery, in elderly, 102
- Pain syndromes, Botox injections for, 190–191
- Palatal myoclonus, Botox injections for, 189
- Palmoplantar warts, in elderly, 14
- Paraneoplastic pemphigus, in elderly, 75–76
- Parathyroid disease, in elderly, 27–28
- Parenteral gold, for psoriatic arthritis, 480
- Paronychia, candidal, in elderly, 44–45
- Peau d'orange chin, Botox injections for, 154–155
- Pediculosis, in elderly, 9–11
- pediculosis capitis, 10
 - pediculosis corporis, 11
 - pediculosis pubis, 10–11
- Pellagra, in elderly, 28–29
- Pemphigus, in elderly. *See* Blistering diseases.
- Penicillins, indications for, in elderly, 67
- Perforating dermatosis, in elderly, 24
- Perianal candidiasis, in elderly, 41
- Pericarditis, smallpox vaccination and, 283
- Perioral rhytides, Botox injections for, 153
- Periorbital rhytides, Botox injections for, 148–149, 201–202
- Perleche, in elderly, 37
- Permethrin, for scabies, in elderly, 8
- Pestis minor, in bioterrorism, 308
- Photochemotherapy, for psoriasis, 381–382, 400–402
- Phototherapy, for psoriasis, 381–382, 397–406
- natural, 397–398
 - photochemotherapy, 400–402
 - psoralen plus ultraviolet A, 381–382, 400–402
 - with calcipotriene, 380
 - with cyclosporine, 404
 - with methotrexate, 404
 - with retinoids, 467–468
- ultraviolet B, 381, 382, 398–400, 468
- with acitretin, 468
 - with alefacept, 422
 - with tazarotene, 472
 - with biologic therapy, 404
 - with calcipotriene, 380, 402
 - with cyclosporine, 404
 - with methotrexate, 403–404
 - with retinoids, 381, 402–403, 467–468, 472
 - with steroids, 402
- Phthiriasis, in elderly, 10–11
- Pilosebaceous skin cancer, in elderly, 94–95
- Pimecrolimus, for psoriasis, 459–463
- and recurrence, 461
 - efficacy of, 460–461
 - follow-up of, 461
 - histopathology of, 462
 - immunology of, 462
 - pharmacogenomics of, 461
 - pharmacokinetics of, 461
 - preclinical profile of, 459–460
 - tolerability of, 461–462
- Pituitary disorders, in elderly, 26–27
- Plague, in bioterrorism, 303–312
- bubonic, 305
 - dermatologic findings in, 308
 - diagnosis of, 307
 - epidemiology of, 306
 - laboratory tests for, 308–309
 - management of, 309–310
 - physical examination for, 307–308
 - plague meningitis, 306
 - pneumonic, 305, 308, 310
 - septicemic, 305
 - transmission of, 306–307
 - vaccine for, 310
- Yersinia pestis* microorganism in, 303–304
- relation to other *Yersinia*, 304–305
- Plague meningitis, in bioterrorism, 306
- Plain films, of psoriatic arthritis, 476
- Plantain, in complementary and alternative medicine, 329
- Plaque psoriasis, alefacept for. *See* Psoriasis, chronic plaque psoriasis.
- Platysma muscle, Botox injections in, 155–156, 161–162
- complications of, 202–203
- Pneumonic plague, in bioterrorism, 305, 308, 310

- Pneumonic tularemia, in bioterrorism, 315–316, 317
- Polidocanol, in sclerotherapy, for varicosities, 502
- Polyiodinated iodine, in sclerotherapy, for varicosities, 502
- Polypharmacy, and cutaneous surgery, in elderly, 101–102
- Porphyria cutanea tarda, in elderly, 80–81
- Postherpetic neuralgia, in elderly, 51, 53–54, 56
- Postthyroidectomy syndrome, in elderly, 27–28
- Pregnancy, as contraindication, to smallpox vaccination, 285
etanercept in, 454
smallpox vaccination in, 282
tularemia in, 318
- Procerus muscle, Botox injections in, 139
- Projectile biological weapons, in bioterrorism, 242–243
- Prosthetics, and cutaneous surgery, in elderly, 102
- Prurigo nodularis, in elderly, 19
- Pruritus, of legs, in elderly, 17
- Pseudomembranous candidiasis, in elderly, 36
- Pseudotumor cerebri, retinoids and, 470
- Psoralen plus ultraviolet A therapy, for psoriasis.
See Phototherapy.
- Psoriasis, alefacept for. *See* Alefacept.
biologic therapy for. *See* Biologic therapy.
efalizumab for. *See* Efalizumab.
etanercept for. *See* Etanercept.
future therapies for, 485–489, 491–497
environmental triggers and, 494
epidemiology and, 491–492
evidence-based, 494–495
genetics and, 492–493
pathomechanisms and, 493
quality-of-life issues in, 493–494
staffing requirements for, 486–488
coding and billing, 487
emergency management, 488
infusion center, 487–488
level of care offered, 488–489
genetics of, 339–347
chromosome 6p21 in, 339–343
number of PSORS1 genes in, 342–343
PSORS1 candidate genes in, 340–342
PSORS1 interval in, 339–340
non-major histocompatibility complex susceptibility loci in, 343–344
- immunopathogenesis of, 349–369, 371–374
antigen-presenting cells in, 352, 372–373
CD1d expression in, 356
chemokines in, 373
cytokines in, 354
dendritic cells in, 353–354
genomics in, 361–363
heat shock proteins in, 355
immune cascade in, 373–374
innate and acquired immunity in, 354–356
interferon-gamma in, 351–353, 356, 358
murine models of, 358–361
natural killer cells in, 354, 356
phenotype in, 356–358
T-cell-mediated autoimmunity in, 349–354
T cells in, 372–374
toll-like receptors in, 355
tumor necrosis factor- α in, 354, 437–439, 449–450
in elderly, 3
- infliximab for. *See* Infliximab.
- pimecrolimus for. *See* Pimecrolimus.
- prebiologic therapy for, 379–388
phototherapy. *See* Phototherapy.
systemic, 382–385
cyclosporine. *See* Cyclosporine.
hydroxyurea, 385
methotrexate. *See* Methotrexate.
mycophenolate mofetil, 385
retinoids. *See* Retinoids.
sulfasalazine, 385
tacrolimus, 384
6-thioguanine, 385
- topical, 379–381
anthralin and tars, 380
retinoids. *See* Retinoids.
steroids. *See* Steroids.
vitamin D analogs. *See* Vitamin D analogs.
- quality-of-life issues in, 389–395
financial impact, 393
mental health impact, 391–392
physical impact, 391
social interactions, 392–393
tools for measuring, 390–391
Dermatology Life Quality Index, 390
Dermatology Quality-of-Life Scales, 390
Psoriasis Disability Index, 390–391
Psoriasis Quality-of-Life Questionnaire-12, 391
versus other diseases, 393
- Psoriasis Disability Index, of quality-of-life issues, in psoriasis, 390–391

- Psoriasis Quality-of-Life Questionnaire-12, in psoriasis, 391
- Psoriatic arthritis, 475–484
alefacept for, 422–423, 481
clinical features of, 475
cyclosporine for, 479
diagnosis of, 476
disability due to, 476–477
etanercept for. *See* Etanercept.
etretinate for, 479
infliximab for, 480
leflunomide for, 479
magnetic resonance imaging of, 476
methotrexate for, 479, 480
parenteral gold for, 480
pathogenesis of, 477–478
plain films of, 476
prevalence of, 475–476
sulfasalazine for, 479, 480
- PSORS1 gene, in psoriasis. *See* Psoriasis, genetics of.
- Ptosis, brow. *See* Brow ptosis.
eyelid, Botox injections and, 143, 200
- Puberophonia, Botox injections for, 189
- Pulmonary disease, and cutaneous surgery, in elderly, 99
- Pustular psoriasis, retinoids for, 467
- Pyrethroids, for pediculosis, in elderly, 10
- Pyrethrums, for pediculosis, in elderly, 10

Q

- Quinupristin-dalfopristin, for cutaneous infections, in elderly, 58–59

R

- Rajneeshes, in bioterrorism, 241
- Reishi mushrooms, in complementary and alternative medicine, 329
- Renal disease, and cutaneous surgery, in elderly, 99
- Reticular dermal skin cancer, in elderly, 94
- 13-cis-Retinoic acid, for psoriasis, 403. *See also* Retinoids.
Retinoids, for psoriasis, 380–381, 383–384, 465–474
and arthralgias and myalgias, 470
and hyperlipidemia, 471

- and pseudotumor cerebri, 470
chemistry and pharmacology of, 465–466
follow-up of, 471
guidelines for, 471–472
hepatotoxicity of, 471
mechanism of action of, 466
monotherapy with, 466–467
mucocutaneous toxicity of, 470
ophthalmic effects of, 471
psychiatric effects of, 471
skeletal toxicity of, 471
teratogenicity of, 470
with etanercept, 469
with immunomodulatory agents, 468–469
with phototherapy, 381, 402–403, 467–468, 472
with steroids, 381

for psoriatic arthritis, 479

- Rheumatoid arthritis, alefacept for, 423
infliximab for, 442

Rhinophyma, in elderly, 106

- Rhus tox, in complementary and alternative medicine, 330

- Rhytides, glabellar. *See* Glabellar rhytides.
in elderly, 105–106
perioral, Botox injections for, 153
periocular, Botox injections for, 148–149, 201–202

- Ricin, in bioterrorism, 257–259
clinical features of, 258
differential diagnosis of, 258
historical aspects of, 257–258
management of, 258–259
pathogenicity of, 258

R.I.S.E., in bioterrorism, 242

- RNA synthesis antibiotics, indications for, in elderly, 67–68

rPA102 vaccine, for anthrax, 254

S

- Salivary disorders, Botox injections for, 191
Dysport injections for, 216
- Scabies, in elderly, 3, 7–9, 17–18
diagnosis of, 8, 18
differential diagnosis of, 8
- Scleredema diabetorum, in elderly, 24–25
- Scleromo, in sclerotherapy, for varicosities, 502
- Sclerodex, in sclerotherapy, for varicosities, 502

- Scleromate, in sclerotherapy, for varicosities, 502
- Sclerotherapy, for varicosities. *See* Varicosities.
- Scurvy, in elderly, 28
- Seborrheic dermatitis, in elderly, 3, 33
- Sebum production, decreased, in menopause, 29
- Sepsis syndrome, hemorrhagic fever viruses and, 297
- Septicemic plague, in bioterrorism, 305
- Silymarin, in complementary and alternative medicine, 327
- Skeletal toxicity, of retinoids, 471
- Skin cancer, in elderly, 93–96
 - biopsy of, 96
 - diagnosis of, 96
 - eccrine, 95
 - epidermal, 94
 - management of, 94–96
 - escharotic compounds in, 95
 - lasers in, 95
 - mechanical destruction in, 95
 - Mohs' micrographic surgery in, 95–96
 - rationale for, 94
 - surgical excision in, 95–96
 - melanocytic, 94, 96
 - pilosebaceous, 94–95
 - reconstructive surgery after, 103
 - reticular dermal, 94
 - sun exposure and, 93
- Skin rashes, smallpox vaccination and, 279
- Skin resurfacing, in elderly, 104–105
- Smallpox, in bioterrorism, 263–274, 275–289
 - antiviral antibody responses in, 266
 - classifications of, 268–270
 - flat type, 269
 - fulminant or hemorrhagic type, 269
 - modified type, 269
 - variola minor, 269–270
 - variola sine eruption, 269
 - clinical features of, 267–268
 - dermatologist's role in, 321–322
 - diagnosis of, 270
 - historical aspects of, 275–277
 - immunology of, 265–266
 - lesion distribution in, 268
 - management of, 271–272
 - pathology of, 267
 - T-cell response in, 265–266
 - transmission of, 267
- vaccine for, 271–272
 - administration of, 277
 - contraindications to, 284–285
 - in development, 286–287
 - in pregnancy, 282
 - reactions to, 277–285
 - safety of, 284
 - viral strains in, 264–265
- Smile lines, Botox injections for, 155
- Smooth muscle disorders, Dysport injections for, 215
- Sneddon-Wilkinson disease, in elderly, 76
- Sodium morrhuate, in sclerotherapy, for varicosities, 502
- Sodium tetradecyl, in sclerotherapy, for varicosities, 501–502
- Soft tissue augmentation, in elderly, 105
- Solar elastosis, in elderly, 115–116
- Sotradecol, in sclerotherapy, for varicosities, 501–502
- Spasmodic dysphonia, Botox injections for, 189
- Spasticity, Botox injections for, 189
 - complications of, 198
- Speech disorders, Botox injections for, 190
- Spider veins, in elderly, 106
- Squamous cell carcinoma, in elderly, 16–17
- Staphylococcal enterotoxins, in bioterrorism, 259–260
 - clinical features of, 259
 - differential diagnosis of, 259
 - management of, 259–260
 - pathogenicity of, 259
- Stasis blisters, in elderly, 82–83
- Stasis dermatitis, in elderly, 3, 18–19
- Steroids, for eczematous diseases, in elderly, 3–4
 - for lichen sclerosis et atrophicus, in elderly, 118
 - for pemphigus vulgaris, in elderly, 74, 75
 - for psoriasis, 379–380
 - with phototherapy, 402
 - with retinoids, 381
- Strabismus, Botox injections for, 191
 - complications of, 198
 - historical aspects of, 132
- Streptomycin, for plague, 309–310
 - for tularemia, 317, 318
- Striated muscle disorders, Dysport injections for, 215

Stromectol, for scabies, in elderly, 9
Stuttering, Botox injections for, 190
Subcorneal pustular dermatosis, in elderly, 76
Sulfasalazine, for psoriasis, 385
 for psoriatic arthritis, 479, 480
Sulfonylureas, for diabetes, adverse effects of, in elderly, 25
Sulfur, for scabies, in elderly, 8–9
Sun exposure, and skin cancer, in elderly, 93
Sweating, excessive. *See* Hyperhidrosis.
Sympathectomy, for hyperhidrosis, 177
Synkinesis, after facial nerve paralysis, Botox injections for, 189

T

T cells, and biologic therapy, for psoriasis, 375
 in immunopathogenesis, of psoriasis, 372–374
Tachyphylaxis, steroids and, 379–380
Tacrolimus, for psoriasis, 384
Tars, for psoriasis, 380
Tazarotene, for psoriasis, 380–381.
 See also Retinoids.
 with phototherapy, 381, 472
 with steroids, 381
Tazarotene, for psoriasis, 469–470, 472
Telangiectasia, in elderly, 106
Telangiectatic matting, sclerotherapy and, 504
Temporomandibular joint disorders, Botox injections for, 192
Teratogenicity, of retinoids, 470
Terbinafine, for onychomycosis, in elderly, 48, 57
 for tinea capitis, in elderly, 36
Tetracyclines, for tularemia, 317–318
6-Thioguanine, for psoriasis, 385
Thrombophlebitis, sclerotherapy and, 504–505
Thrush, in elderly, 36
Thyroid disease, in elderly, 25–26
 and cutaneous surgery, 100
Thyroid eye disease, Dysport injections for, 216
Tics, vocal, Botox injections for, 190
Tinea capitis, in elderly, 33–36

Tinea corporis, in elderly, 39–40
Tinea cruris, in elderly, 40
Tinea manuum, in elderly, 43–44
Tinea pedis, in elderly, 15, 41–44
Tinea unguium, in elderly, 16, 45–49, 51, 56–57
Tinea versicolor, in elderly, 37–39
Toll-like receptors, in immunopathogenesis, of psoriasis, 355
Torticollis, Botox injections for, historical aspects of, 132
Tracheoesophageal puncture, for aphonia, Botox injections in, 190
Tretinoin, for solar elastosis, in elderly, 116
Trichothecene toxins, in bioterrorism, 260–261
 clinical features of, 260
 differential diagnosis of, 260–261
 management of, 261
 pathogenicity of, 260
Tricyclic antidepressants, for postherpetic neuralgia, in elderly, 54
Tuberculosis, latent, reactivation of, etanercept and, 453–454
 infliximab and, 443
Tularemia, in bioterrorism, 313–320
 clinical features of, 314–316
 diagnosis of, 316–317
 differential diagnosis of, 317
 Francisella tularensis in, 313–314
 gastrointestinal, 315
 glandular, 315, 317
 historical aspects of, 314
 in children, 318
 in pregnancy, 318
 management of, 317–318
 oculoglandular, 315
 oropharyngeal, 315, 317
 pneumonic, 315–316, 317
 postexposure prophylaxis for, 318
 prognosis for, 318–319
 typhoidal, 316, 317
 ulceroglandular, 315
 vaccine for, 318
Tumor necrosis factor- α , in immunopathogenesis, of psoriasis, 354, 437–439, 449
Tumor necrosis factor- α blockade, in psoriasis, infliximab mediated. *See* Infliximab

Tylomata, in elderly, 13–14

Typhoidal tularemia, in bioterrorism, 316, 317

U

Ulceroglandular tularemia, in bioterrorism, 315

Ulcers, decubitus, in elderly. *See Decubitus ulcers.*
diabetic, in elderly, 23–24
of leg, in elderly, 19
sclerotherapy and, 505

Ultraviolet B therapy, for psoriasis. *See Phototherapy.*

Upper gum show, Botox injections for, 155

Urinary retention, Botox injections for, 191–192

V

Vaccine, for anthrax, 253–254
for hemorrhagic fever viruses, 299
for plague, 310
for smallpox. *See Smallpox.*
for tularemia, 318

Vaccinia, smallpox vaccination and, 279–280,
282–283

Vaccinia Ankara vaccine, for smallpox, 286–287

Vaccinia immune globulin, for smallpox, 271–272,
280–282

Valacyclovir, for herpes zoster, in elderly, 53
for postherpetic neuralgia, in elderly, 54

Vancomycin, indications for, in elderly, 67

Varicosities, anatomy of, 499–500

classification of, 500
etiology of, 500
sclerotherapy for, 499–506
chromated glycerin in, 502
complications of, 504–505
compression in, 504
detergents in, 501
ethanolamine oleate in, 502
follow-up of, 505
hypertonic saline in, 501
injection techniques for, 503–504
new developments in, 505
osmotic agents in, 501
patient consultation for, 505
patient history and physical examination for,
502–503

polidocanol in, 502

polyiodinated iodine in, 502

Sclerodex in, 502

sodium morrhuate in, 502

sodium tetradearyl in, 501–502

supplies for, 503

Variola, in bioterrorism. *See Smallpox.*

Vascular insufficiency, in elderly, 24

Vascular permeability, hemorrhagic fever viruses
and, 297

Venous insufficiency, of leg, in elderly, 19

Venous lakes, in elderly, 106

Verruca plana, in elderly, 14

Verruca vulgaris, in elderly, 14

Verrucous carcinoma, in elderly, 17

Vesiculobullous tinea pedis, in elderly, 43

Vistide, for smallpox, 272, 280–281

Vitamin C deficiency, in elderly, 28

Vitamin D analogs, for psoriasis, 380

with phototherapy, 380, 402

with psoralen plus ultraviolet A therapy, 380

Vocal cord paralysis, Botox injections for, 190

Vocal tics, Botox injections for, 190

Voice tremor, Botox injections for, 190

Vulvovaginitis, candidal, in elderly, 41

W

Warts, nongenital, in elderly, 14–15

World War I, bioterrorism in, 243–244

World War II, bioterrorism in. *See Bioterrorism,*
historical aspects of.

Writer's cramp, Botox injections for, 188–189

X

Xanthomas, eruptive, in elderly, 24

Xerosis, of leg, in elderly, 17

Y

Yersinia species, in plague, 303–305

Z

Zinc deficiency, in elderly, 29

Zygomaticus lines, Botox injections for, 149

Zyvox, for cutaneous infections, in elderly, 57–58